Introduction
Materials and methods
Mice
Experimental stroke model
Behavioral assessment
Magnetic resonance imaging (MRI)
Histopathological analysis
Analysis of cerebrovascular anatomy
Evaluation of BBB permeability
Glial cell cultures
Neuronal cell culture
Immunofluorescence staining
Quantitative real-time RT-PCR analysis
DNA microarray analysis
Phospho-receptor tyrosine kinase array
Capillary electrophoresis
Enzyme-linked immunosorbent assay (ELISA)
Statistical analysis
Results
EphB2 deficiency reduces brain tissue injury and functional disabilities after ischemic stroke
EphB2 deficiency inhibits the expression of gene sets associated with cell death and inflammation and promotes the expression of gene sets related to synaptic transmission in the CNS after acute ischemic stroke
Pathway Name | NES | NOM p-val | FDR q-val |
---|---|---|---|
Nicotine addiction | 2.41 | < 0.001 | < 0.001 |
Glutamatergic synapse | 2.08 | < 0.001 | 0.001 |
Morphine addiction | 2.03 | < 0.001 | 0.001 |
Retrograde endocannabinoid signaling | 1.97 | < 0.001 | 0.001 |
GABAergic synapse | 1.87 | < 0.001 | 0.005 |
Axon guidance | 1.83 | < 0.001 | 0.007 |
Circadian entrainment | 1.78 | < 0.001 | 0.010 |
Calcium signaling pathway | 1.77 | < 0.001 | 0.011 |
Cocaine addiction | 1.73 | 0.004 | 0.015 |
Salivary secretion | 1.56 | 0.002 | 0.070 |
Neuroactive ligand-receptor interaction | 1.55 | < 0.001 | 0.072 |
Parkinson’s disease | 1.53 | 0.002 | 0.079 |
Dopaminergic synapse | 1.51 | 0.005 | 0.082 |
Platelet activation | − 1.50 | 0.003 | 0.048 |
Central carbon metabolism in cancer | − 1.50 | 0.020 | 0.047 |
Choline metabolism in cancer | −1.50 | 0.003 | 0.046 |
One carbon pool by folate | −1.50 | 0.042 | 0.046 |
Hypertrophic cardiomyopathy (HCM) | −1.51 | 0.012 | 0.043 |
TGF-beta signaling pathway | −1.53 | 0.014 | 0.036 |
Prolactin signaling pathway | −1.54 | 0.007 | 0.036 |
Inflammatory bowel disease (IBD) | −1.55 | 0.018 | 0.031 |
DNA replication | −1.55 | 0.026 | 0.031 |
NOD-like receptor signaling pathway | −1.55 | 0.011 | 0.031 |
Colorectal cancer | −1.55 | 0.009 | 0.031 |
Non-alcoholic fatty liver disease (NAFLD) | −1.56 | 0.002 | 0.029 |
Cell adhesion molecules (CAMs) | −1.58 | 0.002 | 0.027 |
Herpes simplex infection | −1.60 | 0.002 | 0.022 |
Viral myocarditis | −1.61 | 0.002 | 0.021 |
Melanoma | −1.61 | 0.007 | 0.021 |
Bladder cancer | −1.62 | 0.011 | 0.020 |
Galactose metabolism | −1.63 | 0.011 | 0.019 |
Adipocytokine signaling pathway | −1.63 | 0.002 | 0.018 |
Mineral absorption | −1.63 | 0.008 | 0.018 |
Acute myeloid leukemia | −1.64 | 0.011 | 0.017 |
Sphingolipid signaling pathway | −1.65 | < 0.001 | 0.015 |
MAPK signaling pathway | −1.67 | < 0.001 | 0.013 |
Pathways in cancer | −1.67 | < 0.001 | 0.013 |
Hepatitis C | −1.68 | < 0.001 | 0.012 |
Biosynthesis of amino acids | −1.69 | < 0.001 | 0.011 |
Protein digestion and absorption | −1.72 | < 0.001 | 0.008 |
Estrogen signaling pathway | −1.72 | < 0.001 | 0.008 |
Fc epsilon RI signaling pathway | −1.74 | < 0.001 | 0.007 |
Transcriptional misregulation in cancer | −1.74 | < 0.001 | 0.007 |
Natural killer cell mediated cytotoxicity | −1.74 | < 0.001 | 0.007 |
Glioma | −1.74 | < 0.001 | 0.007 |
Regulation of actin cytoskeleton | −1.74 | < 0.001 | 0.007 |
Bacterial invasion of epithelial cells | −1.75 | 0.002 | 0.007 |
Cell cycle | −1.76 | < 0.001 | 0.006 |
Chemokine signaling pathway | −1.76 | < 0.001 | 0.006 |
Arginine and proline metabolism | −1.77 | < 0.001 | 0.005 |
Measles | −1.77 | < 0.001 | 0.006 |
Pancreatic cancer | −1.78 | < 0.001 | 0.005 |
Fc gamma R-mediated phagocytosis | −1.79 | < 0.001 | 0.005 |
HTLV-I infection | −1.79 | < 0.001 | 0.004 |
FoxO signaling pathway | −1.80 | < 0.001 | 0.004 |
Chronic myeloid leukemia | −1.82 | < 0.001 | 0.003 |
Prostate cancer | −1.84 | < 0.001 | 0.003 |
MicroRNAs in cancer | −1.84 | < 0.001 | 0.003 |
Hepatitis B | −1.85 | < 0.001 | 0.002 |
Salmonella infection | −1.85 | 0.002 | 0.002 |
Protein processing in endoplasmic reticulum | −1.87 | < 0.001 | 0.002 |
VEGF signaling pathway | −1.87 | < 0.001 | 0.002 |
Epstein-Barr virus infection | −1.87 | < 0.001 | 0.002 |
Influenza A | −1.88 | < 0.001 | 0.002 |
Spliceosome | −1.92 | < 0.001 | 0.001 |
Phagosome | −1.93 | < 0.001 | 0.001 |
Tuberculosis | −1.93 | < 0.001 | 0.001 |
Chagas disease (American trypanosomiasis) | −1.94 | < 0.001 | 0.001 |
Hematopoietic cell lineage | −1.96 | < 0.001 | 0.001 |
Toll-like receptor signaling pathway | −1.97 | < 0.001 | 0.001 |
Jak-STAT signaling pathway | −1.97 | < 0.001 | 0.001 |
PI3K-Akt signaling pathway | −1.97 | < 0.001 | 0.001 |
Proteasome | −1.98 | < 0.001 | 0.001 |
Apoptosis | −2.00 | < 0.001 | 0.001 |
Rheumatoid arthritis | −2.00 | < 0.001 | 0.001 |
Amoebiasis | −2.00 | < 0.001 | 0.001 |
Antigen processing and presentation | −2.00 | < 0.001 | 0.001 |
Pertussis | −2.05 | < 0.001 | < 0.001 |
Malaria | −2.06 | < 0.001 | < 0.001 |
Staphylococcus aureus infection | −2.06 | < 0.001 | < 0.001 |
Legionellosis | −2.06 | < 0.001 | < 0.001 |
Osteoclast differentiation | −2.07 | < 0.001 | < 0.001 |
B cell receptor signaling pathway | −2.07 | < 0.001 | < 0.001 |
HIF-1 signaling pathway | −2.08 | < 0.001 | < 0.001 |
Leishmaniasis | −2.11 | < 0.001 | < 0.001 |
Proteoglycans in cancer | −2.12 | < 0.001 | < 0.001 |
p53 signaling pathway | −2.13 | < 0.001 | < 0.001 |
Leukocyte transendothelial migration | −2.15 | < 0.001 | < 0.001 |
Complement and coagulation cascades | −2.16 | < 0.001 | < 0.001 |
TNF signaling pathway | −2.17 | < 0.001 | < 0.001 |
NF-kappa B signaling pathway | −2.20 | < 0.001 | < 0.001 |
Toxoplasmosis | −2.22 | < 0.001 | < 0.001 |
Cytokine-cytokine receptor interaction | −2.23 | < 0.001 | < 0.001 |
Small cell lung cancer | −2.27 | < 0.001 | < 0.001 |
Focal adhesion | −2.29 | < 0.001 | < 0.001 |
ECM-receptor interaction | −2.46 | < 0.001 | < 0.001 |